Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 8, 2024

GL261

RRID:CVCL_Y003
Type: Cell Line

Proper Citation

(DSMZ Cat# ACC-802, RRID:CVCL_Y003)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_Y003

Proper Citation: (DSMZ Cat# ACC-802, RRID:CVCL_Y003)

Description: Cell line GL261 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Disease: Mouse glioblastoma

Defining Citation: PMID:16734735, PMID:23248259, PMID:23686484, PMID:25894527, PMID:30084848, PMID:30524896

Comments: Breed/subspecies: C57BL/6., Derived from sampling site: Brain., Omics: HLA class I peptidome analysis by proteomics., Omics: Deep exome analysis., Omics: Cell surface proteome., Transformant: ChEBI; CHEBI:34342; 3-methylcholanthrene (3-MC., Doubling time: ~100-120 hours (DSMZ=ACC-802).

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: GL261

Synonyms: Glioma 261, GLIOMA 261, Glioma-261, GL-261

Cross References: BCRJ:0299, ChEMBL-Cells:CHEMBL4483160, ChEMBL-Targets:CHEMBL4483239, DSMZ:ACC-802, DSMZCellDive:ACC-802, NCI-DTP:Glioma 261, PRIDE:PXD000589, PRIDE:PXD008733, PubChem_Cell_line:CVCL_Y003, Wikidata:Q27547979

ID: CVCL_Y003

Vendor: DSMZ

Catalog Number: ACC-802

Ratings and Alerts

No rating or validation information has been found for GL261.

No alerts have been found for GL261.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 454 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Kirschenbaum D, et al. (2024) Time-resolved single-cell transcriptomics defines immune trajectories in glioblastoma. Cell, 187(1), 149.

Schweiger MW, et al. (2024) Glioblastoma extracellular vesicles modulate immune PD-L1 expression in accessory macrophages upon radiotherapy. iScience, 27(2), 108807.

Rashidi A, et al. (2024) Myeloid cell-derived creatine in the hypoxic niche promotes glioblastoma growth. Cell metabolism, 36(1), 62.

Bai L, et al. (2023) Biomimetic three-dimensional glioma model printed in vitro for the studies of glioma cells and neurons interactions. International journal of bioprinting, 9(4), 715.

Tu L, et al. (2023) Incorporation of a TGF-?2-inhibiting oligodeoxynucleotide molecular adjuvant into a tumor cell lysate vaccine to enhance antiglioma immunity in mice. Frontiers in immunology, 14, 1013342.

van Hooren L, et al. (2023) CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma. Nature cancer, 4(5), 665.

Hou X, et al. (2023) Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma. Journal of translational medicine, 21(1), 198.

Miao Y, et al. (2023) Anti-cancer effect of targeting fibroblast activation protein alpha in glioblastoma through remodeling macrophage phenotype and suppressing tumor

progression. CNS neuroscience & therapeutics, 29(3), 878.

Wang T, et al. (2023) Reversing T Cell Dysfunction to Boost Glioblastoma Immunotherapy by Paroxetine-Mediated GRK2 Inhibition and Blockade of Multiple Checkpoints through Biomimetic Nanoparticles. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 10(9), e2204961.

Turco V, et al. (2023) T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles. Nature communications, 14(1), 771.

Ye S, et al. (2023) Rapid and label-free histological imaging of unprocessed surgical tissues via dark-field reflectance ultraviolet microscopy. iScience, 26(1), 105849.

Li Y, et al. (2023) Glioma-derived LRIG3 interacts with NETO2 in tumor-associated macrophages to modulate microenvironment and suppress tumor growth. Cell death & disease, 14(1), 28.

Chen H, et al. (2023) A nitric-oxide driven chemotactic nanomotor for enhanced immunotherapy of glioblastoma. Nature communications, 14(1), 941.

Zhao Q, et al. (2023) FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells. Nature communications, 14(1), 735.

Zhou S, et al. (2023) Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma. Nature communications, 14(1), 435.

Datta M, et al. (2023) Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models. Proceedings of the National Academy of Sciences of the United States of America, 120(6), e2219199120.

Liu Y, et al. (2023) In Situ Nitric Oxide Gas Nanogenerator Reprograms Glioma Immunosuppressive Microenvironment. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 10(18), e2300679.

Chen Q, et al. (2023) Dynamic change in Siglec-15 expression in peritumoral macrophages confers an immunosuppressive microenvironment and poor outcome in glioma. Frontiers in immunology, 14, 1159085.

Qi Z, et al. (2023) Live-attenuated Japanese encephalitis virus inhibits glioblastoma growth and elicits potent antitumor immunity. Frontiers in immunology, 14, 982180.

Liu X, et al. (2023) Interaction between PD-L1 and soluble VEGFR1 in glioblastoma-educated macrophages. BMC cancer, 23(1), 259.